The ARIAD management team is the right mix of talent, expertise and experience to lead our company as we work to become the leader in the discovery, development and commercialization of precision therapies for patients with rare cancers.
Daniel M. Bollag, Ph.D. has served as our Senior Vice President of Regulatory Affairs and Quality since January 2009. He previously served as Vice President, Regulatory Affairs, for Genzyme Corporation from 2006 to 2008.
From 2002 to 2006, Dr. Bollag held multiple positions at Sanofi-Aventis Pharmaceuticals, including Associate Vice President, Global Regulatory Domain Head, Associate Vice President, Global Regulatory Therapeutic Area Head, and Director, U.S. Regulatory Liaison. Dr. Bollag also served as Director, Project Planning and Management at the Bristol-Myers Squibb Pharmaceutical Research Institute from 2000 to 2002. Earlier in his career, from 1991-2000, he held positions at Merck Research Laboratories including Senior Project Manager, Project Planning and Management, Project Manager, and Senior Research Biochemist, Pharmacology.
Dr. Bollag completed a post-doctoral fellowship at Princeton University, and received his Ph.D. degree in Biochemistry from Cornell University. He earned his B.S. degree in Science and B.A. in French at Pennsylvania State University.
Timothy P. Clackson, Ph.D. has served as our President of Research and Development since June 2010 and our Senior Vice President and Chief Scientific Officer since September 2003. Previously, he served as our Senior Vice President, Science and Technology from June 2002 to September 2003, as our Vice President, Gene Therapy and Genomics from June 2000 to June 2002, as our Director, Gene Therapy from August 1999 to June 2000 and as our Department Head, Gene Therapy Biology from March 1999 to August 1999.
Prior to joining us in December 1994, Dr. Clackson was a postdoctoral fellow at Genentech, Inc., a biotechnology company, from 1991 to 1994, where he studied the molecular basis for human growth hormone function.
Dr. Clackson is on the Board of Directors of MassBio. He received his B.A. degree in Biochemistry from the University of Oxford. He received his Ph.D. degree in Biology from the University of Cambridge, for research conducted at the MRC Laboratory of Molecular Biology into antibody engineering and the development of phage display technology.
Hugh M. Cole joined ARIAD as Senior Vice President and Chief Business Officer in March 2014.
Prior to joining ARIAD, Mr. Cole held senior leadership roles in the rare disease business of Shire Pharmaceuticals, including Vice President of Business Development, Global Franchise Lead, and Senior Vice President, Strategy and Program Management. In his Business Development role, Mr. Cole led several in-licensing/acquisition transactions including the acquisition of Jerini AG. He also led the global development and launch of Firazyr, Shire’s market-leading product for acute attacks of hereditary angioedema. In his Strategy and Program Management role, Mr. Cole led a team of approximately 20 people, with responsibility for strategic planning, portfolio analysis, program management, and due diligence on external transaction opportunities. During Mr. Cole’s tenure at Shire, its rare disease revenue grew from approximately $300 million to over $1.5 billion.
Prior to joining Shire, Mr. Cole was Vice President of Corporate Development at Oscient Pharmaceuticals, where he completed several transactions, including product acquisitions/co-promotion deals that established a commercial revenue stream, as well as regional partnerships that generated upfront, milestone, and royalty payments. From 1998 to 2002, Mr. Cole held business development and planning positions at Millennium Pharmaceuticals and its affiliates.
Mr. Cole was a management consultant with The Wilkerson Group from 1992 to 1998 and began his career in 1987 as an investment analyst, covering biotechnology and pharmaceutical companies, with Fred Alger Management.
Mr. Cole earned a Bachelor of Arts in Chemistry from Harvard University in Cambridge, MA and his MBA in Health Care Management and Finance from the Wharton School in Philadelphia.
Jayne M. Gansler joined ARIAD as Senior Vice President, Human Resources in June 2016.
Ms. Gansler joins ARIAD after having served as the Senior Vice President, Global Head of Human Resources for Genzyme, a Sanofi Company, from 2011 to 2015. Ms. Gansler was Senior Vice President, Global Human Resources for Genzyme Corporation from 2002 until 2011. In this role she served as an advisor to the business in all HR related areas, including global strategic HR partnering, compensation, leadership and organizational development, strategic staffing and program management. Prior to joining Genzyme, Ms. Gansler spent over 15 years with Johnson & Johnson Corporation in a variety of senior human resources roles.
She earned her Bachelor of Arts in Human Resource Management from the University of Massachusetts, Amherst.
Jennifer L. Herron joined ARIAD as Executive Vice President and Chief Commercial Officer in May 2016.
Ms. Herron joined ARIAD after a ten-year career at Bristol-Myers Squibb Company (BMS), where she served as Lead, Commercial Transformation and Operating Model. Previously, Ms. Herron served in various roles of increasing responsibility at BMS, including as Vice President, U.S. Immunology from 2014 to 2016, where she transformed the U.S. immunoscience business unit, returning the business to significant volume and share growth; and as General Manager for BMS in Puerto Rico and the Caribbean from 2012 to 2014, where she was responsible for driving topline performance for the entire BMS portfolio. Ms. Herron also served as Executive Director, U.S. Commercial Operations, for BMS from 2010 to 2012, following several commercial leadership roles in oncology from 2006 through 2009. Prior to joining BMS, Ms. Herron served in critical marketing roles for in-line and launch assets in oncology for both Novartis and GSK/SmithKline Beecham. Ms. Herron started her pharmaceutical career as a clinical research associate at Boehringer Mannheim Pharmaceuticals.
She received a B.A. in Biology and Economics from Lehigh University and an M.B.A. from Georgetown University.